April 3rd. HC Wainwright analyst A. Fein forecasts that the company will earn $0.00 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $25.00 price target on
HC Wainwright & Co.:维持ChromaDex Corporation(CDXC.US)买入评级, 目标价由7.00美元调整至5.50美元。 ChromaDex(CDXC.US)公司简介:Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research ...
Jane Street Group holds 14K shares representing 0.05% ownership of the company. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst ...
a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the HC Wainwright & Co. 26th Annual Global Investment Conference on September 9, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief...
(OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual Global Investmen...
(NASDAQ: FMST) (CSE: FAT) (“Foremost Lithium”, “Foremost” or the “Company”), a North American hard-rock lithium exploration company, today announced it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 at...
(Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26thAnnual Global Investment Conference being held in ...